PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Olaparib, a PARP inhibitor, is effective against various cancers, including prostate cancer. However, resistance to olaparib poses a significant challenge. This study uncovers that mitochondrial alterations and PINK1 gene overexpression contribute to this resistance in prostate cancer cells. Enhanced mitochondrial functionality and increased PINK1 expression in olaparib-resistant cells underscore the importance of targeting mitochondrial dynamics and PINK1 to develop more effective treatments for overcoming olaparib resistance in prostate cancer.
Authors
- Masuda Sharifi (ORCID: https://orcid.org/0000-0001-7759-401X)
- Amy R. Leslie (ORCID: https://orcid.org/0000-0002-6209-022X)
- Alan P. Lombard (ORCID: https://orcid.org/0000-0002-0266-4420)
- Zachary A. Schaaf (ORCID: https://orcid.org/0000-0001-6930-1256)
- Nicholas Mitsiades (ORCID: https://orcid.org/0000-0002-4659-476X)
- Wei Lou (ORCID: https://orcid.org/0000-0003-0989-5560)
- Allen C. Gao (ORCID: https://orcid.org/0000-0002-5966-9038)
- Shu Ning (ORCID: https://orcid.org/0000-0002-6514-0376)
- Ai‐Ming Yu (ORCID: https://orcid.org/0000-0003-1441-4012)
- Chengfei Liu (ORCID: https://orcid.org/0000-0002-2452-8788)
- Richard Y. Gao
- James P. Maine (ORCID: https://orcid.org/0009-0008-3312-3097)
Institutions
- VA Northern California Health Care System (US)
- University of California, Davis (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-10-23
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0339
- Citations
- 5
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- U.S. Department of Defense
- U.S. Department of Veterans Affairs